|Day Low/High||83.91 / 88.15|
|52 Wk Low/High||83.62 / 165.87|
It's challenging to put cash to work but I'll keep digging.
Shares of drug-maker Sarepta are higher Tuesday on the back of an upgrade from RBC, but Jim Cramer says he's not adding shares to his portfolio.
Analysts say the Duchenne muscular-dystrophy treatment could be a "major game changer" for Sarepta Therapeutics.
Billionaire activist investor Carl Icahn helped pull down Chesapeake Energy by unveiling a substantial selloff.
Concerns are starting to pop up that maybe the Fed statement will have a hawkish tone.
A drug approval sends Sarepta skyrocketing, while analysts' actions dominate other market movers.
Stocks hold higher through the morning session as crude oil extends earlier gains.
Buyers expect a dovish Fed and are still trying to put money to work.
Jim Cramer is watching Sarepta shares after an FDA official critical of the drug steps down.
The overall technical condition of the indices remains negative.
Though highly speculative, Sarepta Therapeutics could be a short-term play.
Shares of Sarepta plunged 27 percent on Thursday after the Food and Drug Administration finalized procedures for expanding access to unapproved drugs.
Although markets are flat, Sarepta and Signet have been big movers.
Banks and Biotech are up as the stock market continues to gain momentum.
Jim Cramer talks oil, Citigroup, burger joints and biotechs.
Also, Pfizer-Allergan deal clears another hurdle.
Jim Cramer likes Soutwest (LUV), isn't a fan of Sarepta Therapeutics (SRPT) and will soon have a 'surprise' piece on McDonald's (MCD).
Sarepta Therapeutics is the disaster du jour. The disaster du jour, a stock often mentioned in our comments section (Jack's favorite equity) and on message boards, is Sarepta Therapeutics (SRPT).